Wikipedia
Enadenotucirev
Enadenotucirev is an investigational oncolytic virus that is entering clinical trials for various cancers.
It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as oncolytic vaccine ColoAd1.
It is intended to be modified with additional genes to treat different conditions.
In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) gave a positive review of enadenotucirev to treat platinum-resistant ovarian cancer.